Compare TAC & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TAC | TWST |
|---|---|---|
| Founded | 1909 | 2013 |
| Country | Canada | United States |
| Employees | 1350 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | N/A | 2018 |
| Metric | TAC | TWST |
|---|---|---|
| Price | $12.94 | $44.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $23.67 | ★ $48.75 |
| AVG Volume (30 Days) | ★ 1.3M | 903.2K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | N/A | $18.91 |
| Revenue Next Year | $2.24 | $15.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $7.82 | $23.30 |
| 52 Week High | $17.88 | $57.88 |
| Indicator | TAC | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 46.04 |
| Support Level | $12.08 | $41.65 |
| Resistance Level | $13.94 | $45.76 |
| Average True Range (ATR) | 0.45 | 2.66 |
| MACD | 0.05 | -0.06 |
| Stochastic Oscillator | 76.04 | 26.56 |
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse electrical power generation assets in Canada, the United States, and Western Australia. The company has reportable segments namely, Hydro, Wind & Solar, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.